Qiagen Buys STAT-Dx To Launch Next-Gen Syndromic Testing System

Qiagen has agreed to acquire STAT-Dx, a start-up that developed a multiplex diagnostic for common syndromes, for about $147m in upfront cash, and up to $44m in regulatory and commercial milestones.